| Current prospects for mRNA gene delivery. | |
| | |
MedLine Citation:
|
PMID: 18948192 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Replication-deficient viruses have been used most successfully in the field of gene therapy because of their high transfection efficiency. However, the risk of insertional mutagenesis and induction of unwanted immune responses remains still critical for their safe application. On the other hand, nonviral vectors have been intensively investigated for plasmid DNA (pDNA) delivery as a safer alternative although their gene transfer efficiency is still many folds lower than for viral vectors, which has been predominately attributed to the insufficient transport of pDNA into the nucleus. Instead of pDNA, messenger RNA (mRNA) has recently emerged as an attractive and promising alternative in the nonviral gene delivery field. This strategy combines several advantages compared to pDNA: (i) the nuclear membrane, which is a major obstacle for pDNA, can be avoided because mRNA exerts its function in the cytoplasm; (ii) the risk of insertional mutagenesis can be excluded; (iii) the determination and use of an efficient promoter is omitted; (iv) repeated application is possible; (v) mRNA is also effective in non-dividing cells, and (vi) vector-induced immunogenicity may be avoidable. In this review, we summarize recent improvements of mRNA gene delivery and discuss its opportunities for the usage in gene therapy. |
| | |
Authors:
|
Ayako Yamamoto; Michael Kormann; Joseph Rosenecker; Carsten Rudolph |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2008-10-10 |
Journal Detail:
|
Title: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V Volume: 71 ISSN: 1873-3441 ISO Abbreviation: Eur J Pharm Biopharm Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-03-02 Completed Date: 2009-05-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9109778 Medline TA: Eur J Pharm Biopharm Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 484-9 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Ludwig-Maximilians, University, Munich, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Biological Transport DNA / administration & dosage, immunology Gene Therapy / methods* Gene Transfer Techniques* Genetic Vectors Humans Plasmids / administration & dosage RNA, Messenger / administration & dosage*, immunology |
| Chemical | |
Reg. No./Substance:
|
0/RNA, Messenger; 9007-49-2/DNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: TNF-alpha and IL-6 signals from the bone marrow derived cells are necessary for normal murine liver ...
Next Document: The multienzyme architecture of eukaryotic fatty acid synthases.